COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01363323
Recruitment Status : Completed
First Posted : June 1, 2011
Last Update Posted : November 29, 2019
Information provided by:
Bausch Health Americas, Inc.

Brief Summary:
This study will employ a single-center, randomized, double-blind parallel-group design for MNTX and placebo, with a positive control (moxifloxacin) dosed single-blind to confirm methodology, in normal healthy male and female volunteers. Multiple ECGs will be obtained after single clinical and supratherapeutic doses of MNTX to assess ECG effects compared to placebo.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Methylnaltrexone (MNTX) Drug: Placebo Drug: Moxifloxacin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 546 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo/Positive Controlled, Evaluation of the Effects of MNTX on ECG Parameters and Cardiac Repolarization in Normal Volunteers
Study Start Date : November 2004
Actual Primary Completion Date : January 2005
Actual Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: Methylnaltrexone (MNTX)
Dose 1

Experimental: Arm 2 Drug: Methylnaltrexone (MNTX)
Dose 2

Experimental: Arm 3 Drug: Methylnaltrexone (MNTX)
Dose 3

Placebo Comparator: Arm 4 Drug: Placebo
Active Comparator: Arm 5 Drug: Moxifloxacin

Primary Outcome Measures :
  1. Effects of MNTX on QTcI duration [ Time Frame: 3 days ]
    The primary objective of the study is to compare the effects of clinical and supratherapeutic doses of MNTX with the effects of placebo on QTcI duration in healthy volunteers.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy and free of acute active illnesses
  2. Males and females between the ages of 18 and 45 years, inclusive
  3. Body mass index between 18-30, inclusive, and weight between 50-110 kgs
  4. ECG within normal limits (including PR <220, QRS <110, and QTc <450 ms.)

Exclusion Criteria:

  1. Previous MNTX exposure
  2. Currently pregnant or nursing
  3. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, or other medically significant disorders
  4. Consumption of alcoholic beverages within 7 days prior to study confinement
  5. Any evidence of congenital or familial long-QT syndrome
  6. History of drug abuse of positive findings on urine drug screen
  7. Known allergy or hypersensitivity to MNTX or its excipients, moxifloxacin, opioids, or related drugs or a history or relevant adverse drug reactions of any origin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01363323

Layout table for location information
United States, New York
Progenics Pharmaceuticals
Tarrytown, New York, United States, 10591
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for investigator information
Study Director: Tage Ramakrishna, MD Progenics Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Tage Ramakrishna, M.D., Progenics Pharmaceuticals, Inc. Identifier: NCT01363323    
Other Study ID Numbers: MNTX 1106
First Posted: June 1, 2011    Key Record Dates
Last Update Posted: November 29, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Narcotic Antagonists
Sensory System Agents
Peripheral Nervous System Agents
Alcohol Deterrents